These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 1773911)

  • 1. Effect of prostaglandin E1 on renal haemodynamics in a patient with diabetic nephropathy.
    Okada S; Ogino Y; Ichiki K; Tanokuchi S; Ishii K; Hamada H; Ota Z; Hiraki Y
    J Int Med Res; 1991; 19(6):497-500. PubMed ID: 1773911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of prostaglandin E1 on the renin-aldosterone system in patients with diabetic nephropathy.
    Okada S; Ichiki K; Tanokuchi S; Ishii K; Hamada H; Ota Z
    J Int Med Res; 1993; 21(3):126-32. PubMed ID: 8299855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does a dose of 40 micrograms/day prostaglandin E1 reduce creatinine clearance in a patient with diabetic nephropathy of the nephrotic type?
    Okada S; Hamada H; Ichiki K; Tanokuchi S; Ishii K; Ota Z; Hiraki Y
    J Int Med Res; 1992 Apr; 20(2):190-6. PubMed ID: 1521675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beraprost Sodium Protects Against Diabetic Nephropathy in Patients with Arteriosclerosis Obliterans: A Prospective, Randomized, Open-label Study.
    Shima A; Miyamoto M; Kubota Y; Takagi G; Shimizu W
    J Nippon Med Sch; 2015; 82(2):84-91. PubMed ID: 25959199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of prostaglandin E1 infusion on limb hemodynamics and vasodilatory response in patients with arteriosclerosis obliterans.
    Makita S; Nakamura M; Ohhira A; Itoh S; Hiramori K
    Cardiovasc Drugs Ther; 1997 Jul; 11(3):441-8. PubMed ID: 9310272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of prostaglandin E1 on heavy proteinuria in slightly azotaemic diabetics.
    Okada S; Sato K; Higuchi T; Ichiki K; Tanokuchi S; Ishii K; Hamada H; Ota Z
    J Int Med Res; 1991; 19(2):171-3. PubMed ID: 1864454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased creatinine clearance which may be observed during prostaglandin E1 therapy: is it reversible with discontinuation of therapy?
    Okada S; Miyai Y; Sato K; Higuchi T; Ichiki K; Tanokuchi S; Ishii K; Hamada H; Ota Z
    J Int Med Res; 1991; 19(6):493-6. PubMed ID: 1773910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostaglandin E1 for renal papillary necrosis in a patient with diabetes mellitus.
    Abe K; Ozono Y; Miyazaki M; Furusu A; Shioshita K; Sasaki O; Tsukasaki S; Harada T; Kohno S
    J Int Med Res; 1999; 27(2):90-5. PubMed ID: 10446696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of prostaglandin E1 on slight proteinuria in non-azotaemic diabetics.
    Okada S; Sato K; Higuchi T; Ichiki K; Tanokuchi S; Ishii K; Hamada H; Ota Z
    J Int Med Res; 1992 Feb; 20(1):94-7. PubMed ID: 1568524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postoperative intravenous infusion of alprostadil (PGE1) does not improve renal function in hepatic transplant recipients.
    Manasia AR; Leibowitz AB; Miller CM; Silverstein JH; Schwartz M; Delgiudice R; Vallabhajosula S; Oropello JM; Benjamin E
    J Am Coll Surg; 1996 Apr; 182(4):347-52. PubMed ID: 8605558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prostaglandin E1 in the treatment of chronic ischemia of the extremities].
    Kowal-Gierczak B; Kurzawska-Mielecka M; Czarnacki M
    Pol Arch Med Wewn; 1990 Nov; 84(5):321-7. PubMed ID: 2075125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy.
    Arora MK; Reddy K; Balakumar P
    Eur J Pharmacol; 2010 Jun; 636(1-3):137-44. PubMed ID: 20347778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of trental on indices kidney function in diabetes mellitus].
    Blagosklonnaia IaV; Mamedov R; Kozlov VV; Emanuél' VL; Kudriashova MI
    Probl Endokrinol (Mosk); 1982; 28(3):3-8. PubMed ID: 7100130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of weight loss using formula diet on renal function in obese patients with diabetic nephropathy.
    Saiki A; Nagayama D; Ohhira M; Endoh K; Ohtsuka M; Koide N; Oyama T; Miyashita Y; Shirai K
    Int J Obes (Lond); 2005 Sep; 29(9):1115-20. PubMed ID: 15925953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of patients with occlusive arterial diseases of the legs with prostaglandin E1].
    Dibirov MD
    Vestn Khir Im I I Grek; 1988 Jun; 140(6):137-8. PubMed ID: 3222855
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical experience with prostaglandin E1 in the treatment of arteriosclerosis obliterans. A preliminary report.
    Ambrus JL; Taheri P; Killion D; Donaldson G
    J Med; 1983; 14(1):1-15. PubMed ID: 6577118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Improved kidney function with intravenous prostaglandin E1 in patients with terminal heart failure].
    Wutte M; Hülsmann M; Berger R; Rödler S; Frey B; Stanek B; Pacher R
    Wien Klin Wochenschr; 1998 Jul; 110(13-14):473-8. PubMed ID: 9746960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of thiazolidinedione treatment on proteinuria and renal hemodynamic in type 2 diabetic patients with overt nephropathy.
    Pistrosch F; Passauer J; Herbrig K; Schwanebeck U; Gross P; Bornstein SR
    Horm Metab Res; 2012 Nov; 44(12):914-8. PubMed ID: 22723267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Predicting diabetic nephropathy].
    Mogensen CE; Christensen CK
    Journ Annu Diabetol Hotel Dieu; 1984; ():333-49. PubMed ID: 6399537
    [No Abstract]   [Full Text] [Related]  

  • 20. Decline of renal function is associated with proteinuria and systolic blood pressure in the morning in diabetic nephropathy.
    Suzuki H; Kanno Y; Nakamoto H; Okada H; Sugahara S
    Clin Exp Hypertens; 2005; 27(2-3):129-38. PubMed ID: 15835375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.